China Sets Aside RMB 2.7 Billion To Advance Biopharma Tech
This article was originally published in PharmAsia News
This year, China’s National Development Reform Commission has earmarked RMB 1.2 billion in funding for projects relating to development of generics and protein biopharma and vaccines.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.